大隐静脉急性浅静脉血栓的药物治疗综述
本文综述了6项前瞻性随机对照试验,评估抗凝治疗大隐静脉急性浅静脉血栓的疗效。低分子肝素(LMWH)可降低血栓扩展和复发,尤其采用中间剂量30天时;磺达肝癸钠预防剂量可减少血栓扩展、复发及短期后续VTE风险。最佳剂量和疗程尚不明确。
要点
- LMWH中间剂量用30天可降低血栓扩展和复发。
- 磺达肝癸钠预防剂量减少血栓扩展、复发及短期VTE。
- 最佳抗凝剂量和疗程仍需进一步研究。
核心结论
- 低于治疗剂量的抗凝治疗大隐静脉急性SVT可降低血栓进展、复发及后续VTE风险。
研究设计与样本
- 系统检索MEDLINE数据库,纳入6项前瞻性随机对照试验,比较抗凝与安慰剂或不同剂量/疗程抗凝。
主要发现
- 4项研究使用LMWH,1项大型多中心试验使用因子Xa抑制剂。
- LMWH中间剂量(预防与治疗剂量之间)用30天可降低血栓扩展和复发。
- LMWH对后续VTE风险的影响尚不明确。
- 磺达肝癸钠预防剂量可减少血栓扩展、复发及短期后续VTE风险。
关键数值与推荐
- 广泛性SVT定义为血栓段长度至少5 cm。
- LMWH中间剂量定义为预防与治疗剂量之间的剂量,疗程30天。
临床怎么用
- 大隐静脉广泛急性SVT可考虑抗凝治疗,剂量低于治疗水平。
- LMWH中间剂量30天或磺达肝癸钠预防剂量为可选方案。
- 需个体化评估后续VTE风险与出血风险。
局限性
- LMWH对后续VTE风险的影响尚不明确。
- LMWH最佳剂量和疗程未确定。
- 纳入研究数量有限(6项)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Acute superficial vein thrombosis (SVT) of the axial veins, such as the great saphenous vein (GSV), is a common clinical condition that carries with it significant risk of propagation of thrombus, recurrence, and, most concerning, subsequent venous thromboembolism (VTE). Conservative therapy with nonsteroidal anti-inflammatory medication and heat does not prevent extension of thrombus or protect against recurrent or future VTE in patients with extensive SVT (thrombotic segment of at least 5 cm in length). To prevent future thromboembolic events, anticoagulation has become the treatment of choice for extensive acute SVT in the GSV. In spite of this, the dose and duration of anticoagulation in the treatment of SVT vary widely. This review summarizes the evidence from large prospective, randomized clinical trials on the treatment of SVT with anticoagulation (vs placebo or different doses and durations of anticoagulation) with respect to the outcome measures of thrombus extension, SVT recurrence, and future VTE. METHODS: A systematic search was performed using the MEDLINE database to identify all prospective, randomized controlled trials of treatment with anticoagulation in patients with SVT in the GSV. Six prospective, randomized trials were identified that met the inclusion criteria and were reviewed in detail. RESULTS: Treatment of acute SVT was most commonly managed in an outpatient setting using either low-molecular-weight heparin (LMWH) in four studies or, alternatively, a factor Xa inhibitor in one large multicenter trial. LMWH was associated with a lower rate of thrombus extension and subsequent recurrence, especially when an intermediate dose (defined as a dose between prophylactic and therapeutic doses) was used for a period of 30 days. The full effect of treatment with LMWH on the risk of subsequent VTE remains unclear, as do the optimal dose and duration of this drug. Prophylactic doses of fondaparinux, a factor Xa inhibitor, were found to be beneficial in reducing the rate of thrombus extension and recurrence as well as in reducing the risk of subsequent VTE both during treatment and after cessation of anticoagulation in the short term. CONCLUSIONS: These data suggest that treatment of acute SVT of the GSV with anticoagulation, at doses below therapeutic levels, does offer the benefit of decreased risk of thrombus propagation, recurrence, and, at least in one large randomized clinical trial, subsequent VTE. Future studies to refine optimal dose and duration of anticoagulation to lower the rate of subsequent thromboembolic events and SVT recurrence are needed.
引用
- Scovell SD, Ergul EA, Conrad MF, et al. Medical management of acute superficial vein thrombosis of the saphenous vein. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 29097174. doi:10.1016/j.jvsv.2017.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。